About
The discipline came first
I began as a researcher. After neuroscience and psychology at Brandeis I joined the Framingham Heart Study, where I conducted more than a hundred neuropsychological examinations and wrote each up as a narrative report for the study’s senior investigators. I have written for that reader ever since.
Health sciences communications followed, in New York, Singapore and Los Angeles. In Edelman’s BioScience practice I helped public companies, AstraZeneca among them, prepare for high-profile announcements and for the issues that could follow them. Edelman then moved me to Singapore to lead its health sciences practice for Southeast Asia, with a remit that reached across Asia, the Middle East and Africa. I advised the regional chief executives of pharmaceutical and health companies, worked with government health officials and the leaders of health nonprofits, and co-wrote the firm’s report on Singapore’s health reforms. At KYNE I helped open the Los Angeles office and, as vice president, ran its operations and key accounts.
At AstraZeneca I first led science communications for Oncology R&D. I developed a model for taking a medicine’s science narrative from research to the commercial business and, with the business development and transactions teams, handled the communications around oncology deals. In 2021 the company gave me its Global Corporate Affairs Award for the communications plan I led when Oncology R&D suddenly lost its leader. As senior director of global external communications I then built and led editorial for the rare disease business, a unit with more than seven billion dollars in annual revenue, with the team and agency budgets behind it. I was the lead for its part of the annual report, working with investor relations, and I led the unit’s communications through a change of senior leadership. Much of what I wrote at AstraZeneca went first to investor relations or to legal, compliance and regulatory reviewers, who could check it.